ClinicalTrials.gg
Status unknownNCT03296579Updated May 2, 2018

Non-invasive Ventilation vs. Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma

An interventional study of BiPAP and CPAP in Asthma Acute and Asthma in Children, sponsored by University of British Columbia. Status unknown. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-05-02.

Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Apr 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 20 studies in Asthma by University of British Columbia — 5 open to participants now, 5 under way, none of them phase 3. Asthma · University of British Columbia.

Planned enrollment
3rd of 14
100 · median 52
Started
2018
with 2 others
No phase
11 of 20
2 open now
Registered
11th of 20
by date

Among the 20 studies in Asthma by University of British Columbia, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2018, is one of 11 with no phase, and was the 11th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 20 studies in Asthma by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Asthma by University of British Columbia, or all of them as a file.
02

Study summary

Acute asthma produces greatly increased work of breathing and increased oxygen requirement secondary to bronchial narrowing and airway obstruction by inflammatory secretions. There is growing evidence that non-invasive ventilation can reverse these processes more efficiently than conventional asthma therapy. Surprisingly, there have not yet been any large scale prospective controlled studies to investigate this hypothesis, (either in adults or children). Consequently, the aim of this study is to determine if the use of non-invasive positive airway pressure, for children admitted to hospital with an acute exacerbation of asthma, reduces their work of breathing, need for adjunctive medications, and shortens the length of hospital stay, compared to current standard therapy.

Read the detailed description

The aim of the study is to determine if the use of NIV, for children admitted to hospital with an acute exacerbation of asthma, reduces their work of breathing, need for adjunctive medication, length of hospital stay, and need for intubation and mechanical ventilation. Study design will be prospective, randomized and controlled. The tightly fitting face mask necessary for NIV makes it impossible to make this a blinded study.

The principal enrollment criteria will be children over 2 years of age presenting to the ER with acute asthma. After diagnosis, all children are treated with standard therapy (systemic steroids plus 3 doses of inhaled salbutamol and 1 dose of inhaled ipratropium over a 1 hour period then hourly salbutamol). The principal decision between discharge track and admission track will be made at 2 hours after first steroid dose. Admission criteria are based on sequential PRAM scores.

After initial asthma treatment and observation in the emergency room, to determine which patients can be discharged home, those who need admission will be asked to join the study, then consented and randomized. There will be three treatment groups:

  • BiPAP: standard steroid dose, hourly salbutamol and BiPAP at 15/5 cm H2O by face mask with rate 10 to 15/min, oxygen as needed.
  • CPAP: standard steroid dose, hourly salbutamol and 8 to 10 cm H2O constant pressure by face mask, oxygen as needed.
  • Conventional therapy: standard steroid dose plus hourly nebulized salbutamol, nebulized ipratropium q 6 hrly, magnesium sulphate 50 mg/kg IV (4 doses q 6 hrly), loading dose of aminophylline 6 mg/kg IV if no progress, oxygen as needed.

All children will be admitted to a small 3 bed respiratory unit. They will be closely monitored and objectively scored every 4 hours using the PRAM asthma clinical severity score (Pediatric Respiratory Assessment Measure). Projected patient enrollment will be at least 30 in each arm. Estimated study duration is 6 months.

03

Conditions studied

  • Asthma Acute
  • Asthma in Children

Browse trials for

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 2-18 years old
  • Clinical diagnosis of acute asthma exacerbation (respiratory rate greater than WHO's age-dependent criteria, a history of similar previous episodes and wheezing heard on auscultation by an experienced physician)
  • PRAM score of 8 or more after 2 hours post- administration
  • Parents willing and able to sign consent
  • Children over the age of 6 willing to provide assent

Exclusion criteria

Exclusion Criteria:

  • Clinical suspicion of bacterial pneumonia: focal crackles or bronchial breathing, and/or major chest x-ray findings.
  • Impending respiratory failure at presentation requiring direct PICU admission
  • Any to BiPAP use including altered mental status, recent bowel surgery, intractable vomiting, inability to protect airway, pneumothorax.
  • Receiving maintenance dose of oral at time of hospital admission
  • History of serious unrelated illness such as congenital heart disease or bronchopulmonary dysplasia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Conventional asthma therapy.

    Bilevel Positive Airway Pressure group(BiPAP). BiPAP settings at 15/5 cm H2O by face mask with background rate 10 to 15/min. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 \> 92%.

    Drug: Ipratropium · Drug: Magnesium Sulfate · Drug: Aminophylline · Drug: Standard steroid dose, hourly salbutamol, oxygen as needed

  • Experimental
    Non-invasive ventilation (CPAP).

    Continuous Positive Airway Pressure group (CPAP). CPAP settings at 8 to 10 cm H2O. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 \> 92%.

    Device: CPAP · Drug: Standard steroid dose, hourly salbutamol, oxygen as needed

  • Experimental
    Non-invasive ventilation (BiPAP)

    Standard steroid dose, hourly salbutamol, oxygen as needed, nebulized ipratropium q 6 hrly, magnesium sulfate 50 mg/kg IV (4 doses q 6 hrly), loading dose of aminophylline 6 mg/kg IV if no progress.

    Device: BiPAP · Drug: Standard steroid dose, hourly salbutamol, oxygen as needed

Interventions

  • DeviceBiPAP

    The patient's breathing is assisted by cycling between high and low pressures at a pre-set rate.

    Also known as: Trilogy BiPAP, Bilevel Positive Airway Pressure

  • DeviceCPAP

    The patient breathes against a constant pressure delivered by face mask.

    Also known as: Continuous Positive Airway Pressure

  • Nebulized q6h

  • 50mg/kg IV, 4 doses q6h

  • 6mg/kg IV (if no progress)

  • DrugStandard steroid dose, hourly salbutamol, oxygen as needed

    Standard common therapies for all three arms.

06

What researchers measure

Primary outcomes

  1. Time to reach a PRAM score of ≤3

    PRAM score includes assessment of oxygen saturations, suprasternal retractions, scalene muscle contraction, air entry and wheezing.

    Time frame: Patients will be followed for the duration of their hospital stay (an estimated average duration of 4 days)

Secondary outcomes

  1. Time to room air

    Time that oxygen is required

    Time frame: Patients will be followed for the duration of their hospital stay (an estimated average of 4 days).

  2. Total medication use per 12 hr period

    Comparison of total medication use by children in each arm.

    Time frame: Patients will be followed for the duration of their hospital stay (an estimated average of 4 days).

  3. Numbers failing treatment and transferred to ICU

    Number of patients in each group that fail treatment and require transfer to ICU

    Time frame: Patients will be followed for the duration of their hospital stay (an estimated average of 4 days).

Other outcomes

  1. Time to reach FEV1 >80% predicted in those children able to perform pulmonary function tests

    Standard pulmonary function tests can usually be performed by children \>6 years.

    Time frame: Patients will be followed for the duration of their hospital stay (an estimated average of 4 days).

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Gowraiah V, Awasthi S, Kapoor R, Sahana D, Venkatesh P, Gangadhar B, Awasthi A, Verma A, Pai N, Seear M. Can we distinguish pneumonia from wheezy diseases in tachypnoeic children under low-resource conditions? A prospective observational study in four Indian hospitals. Arch Dis Child. 2014 Oct;99(10):899-906. doi: 10.1136/archdischild-2013-305740. Epub 2014 Jun 12. PubMed 24925892 ↗
  • Basnet S, Mander G, Andoh J, Klaska H, Verhulst S, Koirala J. Safety, efficacy, and tolerability of early initiation of noninvasive positive pressure ventilation in pediatric patients admitted with status asthmaticus: a pilot study. Pediatr Crit Care Med. 2012 Jul;13(4):393-8. doi: 10.1097/PCC.0b013e318238b07a. PubMed 22067982 ↗
  • Ducharme FM, Chalut D, Plotnick L, Savdie C, Kudirka D, Zhang X, Meng L, McGillivray D. The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers. J Pediatr. 2008 Apr;152(4):476-80, 480.e1. doi: 10.1016/j.jpeds.2007.08.034. Epub 2007 Oct 31. PubMed 18346499 ↗
  • Martinez FD, Vercelli D. Asthma. Lancet. 2013 Oct 19;382(9901):1360-72. doi: 10.1016/S0140-6736(13)61536-6. Epub 2013 Sep 13. PubMed 24041942 ↗
  • Nava S, Hill N. Non-invasive ventilation in acute respiratory failure. Lancet. 2009 Jul 18;374(9685):250-9. doi: 10.1016/S0140-6736(09)60496-7. PubMed 19616722 ↗
  • British Thoracic Society Standards of Care Committee. Non-invasive ventilation in acute respiratory failure. Thorax. 2002 Mar;57(3):192-211. doi: 10.1136/thorax.57.3.192. No abstract available. PubMed 11867822 ↗
  • Nievas IF, Anand KJ. Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit. J Pediatr Pharmacol Ther. 2013 Apr;18(2):88-104. doi: 10.5863/1551-6776-18.2.88. PubMed 23798903 ↗
  • Papiris SA, Manali ED, Kolilekas L, Triantafillidou C, Tsangaris I. Acute severe asthma: new approaches to assessment and treatment. Drugs. 2009;69(17):2363-91. doi: 10.2165/11319930-000000000-00000. PubMed 19911854 ↗
  • Green E, Jain P, Bernoth M. Noninvasive ventilation for acute exacerbations of asthma: A systematic review of the literature. Aust Crit Care. 2017 Nov;30(6):289-297. doi: 10.1016/j.aucc.2017.01.003. Epub 2017 Jan 27. PubMed 28139368 ↗
  • Soroksky A, Klinowski E, Ilgyev E, Mizrachi A, Miller A, Ben Yehuda TM, Shpirer I, Leonov Y. Noninvasive positive pressure ventilation in acute asthmatic attack. Eur Respir Rev. 2010 Mar;19(115):39-45. doi: 10.1183/09059180.00006109. PubMed 20956164 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2018; primary completion for Nov 2018, 5 months later.

Of 600 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 5 months is below that.

Counting every sponsor, half of 650 studies reached it within 23 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2017
First posted
Sep 28, 2017
StartEst.
Jun 2018
Primary completionEst.
Nov 2018
CompletionEst.
Dec 2018
Last update
May 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03296579
Responsible party
Michael Seear (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Sep 28, 2017
Start date
Jun 2018 (estimated)
Primary completion
Nov 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
May 2, 2018

Study contacts

Michael Seear, MD
Contact
mseear@cw.bc.ca
6048752000
Terry Viczko
Contact
tviczko@bcchr.ca
6048752345 ext. 5419
Michael Seear
principal investigator · University of British Columbia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion